Cue Biopharma Inc. (CUE) Begins Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA (pembrolizumab)

Go back to Cue Biopharma Inc. (CUE) Begins Patient Dosing in Phase 1 Study of CUE-101 in Combination with KEYTRUDA (pembrolizumab)
(NASDAQ: CUE) Delayed: 12.95 -1.09 (7.76%)
Previous Close $14.04    52 Week High
Open $14.04    52 Week Low
Day High $14.30    P/E N/A 
Day Low $12.56    EPS
Volume 460,213